Related Experiment Video
Updated: Sep 5, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Is Severity Score Associated With Indication for Hematopoietic Stem Cell Transplantation in Individuals With Sickle
Miriam V Flor-Park1, Mina Cintho Ozahata2, Isabel Cristina Gomes Moura3
1Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Instituto da Criança, São Paulo, Brazil.
Insights
A validated severity score for sickle cell disease (SCD) did not differentiate between adult patients who were candidates for hematopoietic stem cell transplantation (HSCT) and those who were not. This suggests current HSCT criteria may need re-evaluation to identify all eligible severe SCD patients.
Area of Science:
- Hematology
- Medical Informatics
- Public Health
Background:
- Sickle cell disease (SCD) causes significant morbidity and reduced life expectancy, beginning in childhood.
- Hematopoietic stem cell transplantation (HSCT) offers a curative option for SCD but carries inherent mortality risks.
- Balancing HSCT risks against SCD burden is crucial for treatment decisions.
Purpose of the Study:
- To calculate SCD severity scores in a Brazilian cohort using a validated Bayesian network model.
- To compare these scores between individuals with and without indications for HSCT based on Brazilian Ministry of Health (MoH) criteria.
- To assess the score's utility in identifying HSCT candidates.
Main Methods:
- Observational, retrospective study of 2063 individuals with sickle cell anemia from the Brazil SCD cohort.
- Application of a previously validated Bayesian network-derived severity score.
- Comparison of scores between HSCT candidates (n=431) and non-candidates (n=1632) using classical statistical methods.
Main Results:
- No significant difference in severity scores was observed between adult participants with (mean 0.342) and without (mean 0.292) HSCT indications.
- Median scores were also similar (0.194 vs. 0.183, P=0.354).
- Receiver operating characteristic curves did not identify a clear threshold for differentiating HSCT candidates.
Conclusions:
- The validated severity score, while potentially predicting mortality risk, does not effectively differentiate HSCT candidates in this cohort.
- Current Brazilian MoH criteria for HSCT in SCD may require evaluation to ensure all patients with severe disease who could benefit are identified.
- Further research is needed to refine tools for identifying optimal HSCT candidates in sickle cell disease.
Abstract:
Manifestations of sickle cell disease (SCD) begin early in childhood and cause morbidity and decreased life expectancy. Hematopoietic stem cell transplantation (HSCT) is curative but associated with risk of mortality attributable to the transplant. This risk should be counterbalanced with SCD morbidity and mortality. A severity score using a Bayesian network model was previously validated to predict the risk of death in adult individuals with SCD. The objective of this study is to calculate the severity scores of participants in a multicenter cohort of Brazilians with SCD, using a previously published Bayesian network-derived score, associated with risk of death and then compare the severity scores between participants with and without an indication for HSCT as defined by the Brazilian Ministry of Health (MoH) criteria. This is an observational, retrospective study. We analyzed 2063 individuals with sickle cell anemia from the Recipient Epidemiology and Donor Evaluation Study-III Brazil SCD cohort and applied a Bayesian network-derived score to compare candidates and non-candidates for HSCT according to the Brazilian MoH transplant criteria. Classical statistical methods were used to analyze data and make comparisons. We compared severity scores between cohort members with (n = 431) and without (n = 1632) HSCT indications according to Brazilian MoH. Scores were not different in adult participants with ≥1 HSCT indication when compared to those with no indication (mean 0.342 versus 0.292; median 0.194 versus 0.183, P = .354) and receiver operating characteristic curves did not demonstrate an obvious threshold to differentiate participants with or without HSCT indications. Severity score may predict risk of death but does not differentiate HSCT candidates. Current indications should be evaluated to ensure that patients with more severe disease who might benefit from HSCT are appropriately identified.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Multiple Allele Traits
Regulation of Hematopoietic Stem Cells
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

